drugset / Trial / NCT00159770

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

NCT00159770

Phase 3 Completed 290 enrolled Viatris Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice

Timeline

Start
2001-11
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 10 mg
Subject Olanzapine Small molecule 20 mg
Subject Quetiapine Small molecule 300 mg
Subject Quetiapine Small molecule 750 mg
Subject Risperidone Other / unclassified 4 mg
Subject Risperidone Other / unclassified 8 mg
Subject Ziprasidone Small molecule 80 mg
Subject Ziprasidone Small molecule 160 mg